Plain-English translation of NCT05869474 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new combination approach for advanced pancreatic cancer that has spread. Some patients will receive Gemcitabine plus albumin paclitaxel chemotherapy alone, while others will receive the same chemotherapy plus a procedure where radioactive iodine-125 seeds are implanted directly into the pancreatic tumor using a special ultrasound-guided needle. The goal is to see whether adding local radiation therapy to standard chemotherapy helps people live longer and manage their cancer better.
Pancreatic cancer is very difficult to treat, especially when it has spread to other parts of the body. While chemotherapy is the standard treatment, researchers want to know whether combining it with a targeted radiation approach—delivering radioactive seeds directly to the tumor—might improve survival and give patients better outcomes.
You likely qualify if…
You likely don't qualify if…
If you are randomly chosen for the combination group, you will first undergo a procedure where a doctor uses an ultrasound probe passed through your mouth to guide the placement of radioactive seeds directly into your pancreatic tumor—this is a minimally invasive procedure that does not require major surgery. Two days later, you will begin chemotherapy, receiving infusions on specific days in 21-day cycles. If you are in the comparison group, you will receive only the chemotherapy infusions on the same schedule. Throughout the trial, you will have regular appointments to monitor how well the treatment is working and to check for any side effects.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
China